Agenus Bolsters Medical Affairs to Meet Rising Demand for Experimental Immunotherapy
Event summary
- Agenus is expanding its global Medical Affairs infrastructure and early-access support capabilities.
- Physicians worldwide are increasingly requesting authorized access to the botensilimab plus balstilimab (BOT+BAL) immunotherapy combination.
- BOT+BAL is already being administered through paid named-patient programs in South America, Central America, Europe (UK, Switzerland), and France’s AAC framework (covering three tumor types).
- The AAC framework in France now reimburses BOT+BAL for eligible patients across three advanced solid tumors.
- Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials.
The big picture
Agenus's expansion highlights a growing trend of pharmaceutical companies leveraging regulatory-authorized early access pathways to generate early revenue and gather real-world data for investigational therapies. This strategy is particularly relevant for treatments targeting rare or difficult-to-treat cancers where traditional clinical trial recruitment can be challenging. The reliance on named-patient programs, however, introduces complexities around pricing, reimbursement, and ethical considerations that require careful management.
What we're watching
- Regulatory Scrutiny
- The reliance on named-patient programs and compassionate access frameworks exposes Agenus to potential regulatory changes or increased scrutiny regarding pricing and access protocols.
- Commercial Viability
- The sustainability of these early-access programs, particularly those involving out-of-pocket payments, will depend on demonstrating clinical efficacy and managing patient expectations.
- BATTMAN Trial
- The success of the Phase 3 BATTMAN trial in refractory colorectal cancer will be critical for securing broader regulatory approval and commercial viability of BOT+BAL.
Related topics